Argenx
ARGX
#406
Rank
A$88.51 B
Marketcap
A$1,415
Share price
-2.76%
Change (1 day)
35.47%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): A$23.66

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$22.12. In 2025 the company made an earnings per share (EPS) of A$29.50 an increase over its 2024 EPS that were of A$19.48.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$23.66-19.78%
2025A$29.5051.44%
2024A$19.48-369.77%
2023A-$7.22-60.46%
2022A-$18.2663.33%
2021A-$11.18-40.37%
2020A-$18.75183.47%
2019A-$6.61123.09%
2018A-$2.9754.93%
2017A-$1.9114.07%
2016A-$1.6813.05%
2015A-$1.48-36.34%
2014A-$2.33209.04%
2013A-$0.75-33.99%
2012A-$1.14185.59%
2011A-$0.40